Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 12/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 9/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 8/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.44 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.44 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | ALB | P02768 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | RARB | P10826 | 1/20 | 0.44 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.44 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27513381 | 0.87 | FDFT1 (0.38) | PTGS2ALOX5CYP1A2 | |
| SCHEMBL22735874 | 0.84 | EPHX1 (0.46) | ALOX5 | |
| SCHEMBL23269964 | 0.82 | FDFT1 (0.35) | PTGS2AKR1C3AKR1C2PTGS1LMNA | |
| SCHEMBL18492922 | 0.82 | FDFT1 (0.35) | PTGS2AKR1C3AKR1C2PTGS1LMNA | |
| SCHEMBL7962599 | 0.81 | PTGS2 (0.50) | PTGS2AKR1C3AKR1C2PTGS1LMNA | |
| SCHEMBL30489970 | 0.81 | HPGD (0.41) | PTGS2PTGS1TSHRESR1CYP1A2 | |
| SCHEMBL25295103 | 0.81 | HPGD (0.41) | PTGS2PTGS1TSHRESR1CYP1A2 | |
| SCHEMBL31240148 | 0.79 | PTGS2 (0.48) | PTGS2AKR1C3AKR1C2PTGS1LMNA | |
| SCHEMBL600851 | 0.79 | PTGS2 (0.48) | PTGS2AKR1C3AKR1C2PTGS1LMNA | |
| SCHEMBL6069855 | 0.79 | PTGS2 (0.49) | PTGS2AKR1C3AKR1C2PTGS1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219961-A1 | Pyridine acetamide derivative serving as CDK inhibitor, and preparation method therefor and use thereof | Suzhou Alphama Biotechnology Co., Ltd. (CN) | 2023-07-13 | — | — | US | disclosed |
| US-20230219961-A1 | Pyridine acetamide derivative serving as CDK inhibitor, and preparation method therefor and use thereof | Suzhou Alphama Biotechnology Co., Ltd. (CN) | 2023-07-13 | — | — | US | disclosed |
| CN-115340555-A | Pyridine acetamide derivative as CDK inhibitor, and preparation method and application thereof | 苏州阿尔脉生物科技有限公司 | 2022-11-15 | — | — | CN | disclosed |
| CN-113173924-B | Pyridine acetamide derivative as CDK inhibitor, and preparation method and application thereof | 苏州阿尔脉生物科技有限公司 | 2022-07-19 | — | — | CN | disclosed |
| CN-113173924-A | Pyridine acetamide derivative as CDK inhibitor, and preparation method and application thereof | 苏州阿尔脉生物科技有限公司 | 2021-07-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219961-A1 | Pyridine acetamide derivative serving as CDK inhibitor, and preparation method therefor and use thereof | CDK9, CDK7, CDK8 | PTGS2 2365/4885AKR1C3 885/4885AKR1C2 458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.